Literature DB >> 21169059

Cetuximab in NSCLC: another trial needed.

Francesco Perrone1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21169059     DOI： 10.1016/S1470-2045(10)70289-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

Authors:  Michael L Maitland; Matthew R Levine; Mario E Lacouture; Kristen E Wroblewski; Christine H Chung; Ilyssa O Gordon; Livia Szeto; Gail Ratko; Keyoumars Soltani; Mark F Kozloff; Philip C Hoffman; Ravi Salgia; David P Carbone; Theodore G Karrison; Everett E Vokes
Journal:  BMC Cancer       Date:  2014-01-04       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.